Tweet
Spero Therapeutics Inc (NASDAQ:SPRO) â€“ Equities researchers at Cantor Fitzgerald increased their FY2018 earnings estimates for shares of Spero Therapeutics in a research note issued on Monday, August 13th. Cantor Fitzgerald analyst L. Chen now anticipates that the company will earn ($2.64) per share for the year, up from their prior forecast of ($3.85). Cantor Fitzgerald has a "Buy" rating and a $27.00 price objective on the stock. Cantor Fitzgerald also issued estimates for Spero Therapeutics' FY2019 earnings at ($3.35) EPS. Get Spero Therapeutics alerts:
Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Thursday, August 9th. The company reported ($0.69) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.77) by $0.08. Spero Therapeutics had a negative return on equity of 132.11% and a negative net margin of 1,479.91%. The company had revenue of $0.46 million for the quarter, compared to analysts' expectations of $0.62 million. SPRO has been the topic of several other research reports. Oppenheimer set a $30.00 target price on Spero Therapeutics and gave the company a "buy" rating in a research note on Monday, July 9th. HC Wainwright started coverage on Spero Therapeutics in a research note on Friday, May 11th. They set a "buy" rating and a $28.00 target price on the stock. Zacks Investment Research raised Spero Therapeutics from a "hold" rating to a "buy" rating and set a $12.00 target price on the stock in a research note on Wednesday. Finally, ValuEngine raised Spero Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, May 2nd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Spero Therapeutics has an average rating of "Buy" and a consensus target price of $24.60.
NASDAQ:SPRO opened at $10.50 on Wednesday. Spero Therapeutics has a fifty-two week low of $9.66 and a fifty-two week high of $19.00. The stock has a market cap of $204.76 million and a price-to-earnings ratio of -0.59.
In other news, CFO Joel Sendek sold 2,000 shares of Spero Therapeutics stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $17.50, for a total transaction of $35,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . Also, insider Ankit Mahadevia sold 4,676 shares of Spero Therapeutics stock in a transaction dated Friday, July 6th. The shares were sold at an average price of $17.63, for a total value of $82,437.88. The disclosure for this sale can be found here . In the last ninety days, insiders have sold 10,676 shares of company stock worth $187,438. Company insiders own 26.90% of the company's stock.
Institutional investors have recently made changes to their positions in the company. DAFNA Capital Management LLC lifted its holdings in shares of Spero Therapeutics by 490.9% during the 1st quarter. DAFNA Capital Management LLC now owns 29,544 shares of the company's stock valued at $421,000 after buying an additional 24,544 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Spero Therapeutics by 19,604.3% during the 1st quarter. JPMorgan Chase & Co. now owns 256,353 shares of the company's stock valued at $3,653,000 after buying an additional 255,052 shares during the last quarter. Deutsche Bank AG acquired a new stake in shares of Spero Therapeutics during the 4th quarter valued at about $155,000. BVF Inc. IL lifted its holdings in shares of Spero Therapeutics by 1.9% during the 1st quarter. BVF Inc. IL now owns 1,048,958 shares of the company's stock valued at $14,948,000 after buying an additional 19,773 shares during the last quarter. Finally, BlackRock Inc. acquired a new stake in shares of Spero Therapeutics during the 4th quarter valued at about $2,830,000. Institutional investors and hedge funds own 45.99% of the company's stock.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.
Further Reading: Dividend Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter 